Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.

导出 LinkOut

翻译打印收藏纠错

作者： Joanna Wai Yee,Leong ^[1] ; Peter P,Cheung ^[2] ; Sajeewani,Dissanayake ^[3] ; Warren Weng Seng,Fong ^[2] ; Keng Hong,Leong ^[4] ; Ying Ying,Leung ^[5] ; Anita Yee Nah,Lim ^[4] ; Nai Lee,Lui ^[2] ; Mona,Manghani ^[3] ; Amelia,Santosa ^[6] ; Melonie Kannamma,Sriranganathan ^[7] ; Ernest,Suresh ^[2] ; Teck Choon,Tan ^[3] ; Gim Gee,Teng ^[1] ; Manjari,Lahiri ^[8]

作者单位： Department of Medicine, Changi General Hospital, Singapore, Singapore. ^[1] Division of Rheumatology, University Medicine Cluster, National University Hospital, National University Health System, Singapore, Singapore. ^[2] Department of Medicine, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore. ^[3] Department of Rheumatology and Immunology, Singapore General Hospital, Singapore. ^[4] Leong Keng Hong Arthritis and Medical Clinic, Singapore, Singapore. ^[5] Lui Centre for Arthritis & Rheumatology, Gleneagles Medical Centre, Singapore, Singapore. ^[6] Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore. ^[7] Department of Medicine, Ng Teng Fong General Hospital, Singapore, Singapore. ^[8] Department of Medicine, Khoo Teck Puat Hospital, Singapore, Singapore. ^[9]

关键词 biologic consensus reimbursement rheumatoid arthritis subsidy targeted-synthetic